SCHEMBL1095692

SCHEMBL1095692

CC(C)(C)c1ccc(S(=O)(=O)Nc2cc(F)ccc2C(=O)NN)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD17B2 P37059 7/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
UQCRB P14927 1/20 0.48
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CCR9 P51686 2/20 0.47
HDAC3 O15379 2/20 0.46
HDAC11 Q96DB2 2/20 0.46
HDAC8 Q9BY41 2/20 0.46
HDAC6 Q9UBN7 2/20 0.46
CCR2 P41597 1/20 0.46
MOGAT2 Q3SYC2 1/20 0.46
PTPN5 P54829 1/20 0.46
FLT1 P17948 1/20 0.46
FLT4 P35916 1/20 0.46
KDR P35968 1/20 0.46
KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1094796 0.87 MEN1 (0.52) HSD17B2MEN1KMT2AUQCRBCA1
SCHEMBL1094560 0.86 PTPN5 (0.57) HSD17B2UQCRBCCR9CCR2PTPN5
SCHEMBL1093676 0.86 HSD17B2 (0.66) HSD17B2CCR9CCR2FLT1FLT4
SCHEMBL1109031 0.84 HSD17B2 (0.51) HSD17B2MEN1KMT2AUQCRBCA1
SCHEMBL1094792 0.83 HSD17B2 (0.54) HSD17B2MEN1KMT2AUQCRBCCR9
SCHEMBL23879526 0.82 HSD17B2 (0.41) HSD17B2UQCRBCCR9HDAC3HDAC11
SCHEMBL24268097 0.81 CCR9 (0.42) HSD17B2UQCRBCCR9CCR2MOGAT2
SCHEMBL23877645 0.81 MOGAT2 (0.42) HSD17B2UQCRBCCR9HDAC3HDAC11
SCHEMBL1094267 0.79 CCR9 (0.66) HSD17B2CCR9CCR2FLT1FLT4
SCHEMBL23879525 0.78 CCR9 (0.41) HSD17B2UQCRBCA1CA2CCR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481579-B2 Triazolyl phenyl benzenesulfonamides CHEMOCENTRYX, INC. (US) 2013-07-09 US disclosed
US-8481579-B2 Triazolyl phenyl benzenesulfonamides CHEMOCENTRYX, INC. (US) 2013-07-09 US disclosed
US-8481579-B2 Triazolyl phenyl benzenesulfonamides CHEMOCENTRYX, INC. (US) 2013-07-09 US disclosed
US-20120165303-A1 TRIAZOLYL PHENYL BENZENESULFONAMIDES CHEMOCENTRYX, INC. (US) 2012-06-28 US disclosed
US-20120165303-A1 TRIAZOLYL PHENYL BENZENESULFONAMIDES CHEMOCENTRYX, INC. (US) 2012-06-28 US disclosed
US-20120165303-A1 TRIAZOLYL PHENYL BENZENESULFONAMIDES CHEMOCENTRYX, INC. (US) 2012-06-28 US disclosed
US-8153818-B2 Triazolyl phenyl benzenesulfonamides CHEMOCENTRYX, INC. (US) 2012-04-10 US disclosed
US-8153818-B2 Triazolyl phenyl benzenesulfonamides CHEMOCENTRYX, INC. (US) 2012-04-10 US disclosed
US-8153818-B2 Triazolyl phenyl benzenesulfonamides CHEMOCENTRYX, INC. (US) 2012-04-10 US disclosed
EP-2046762-B1 TRIAZOLYL PHENYL BENZENESULFONAMIDES CHEMOCENTRYX INC (US) 2011-02-16 EP disclosed
US-20100190762-A1 TRIAZOLYL PHENYL BENZENESULFONAMIDES CHEMOCENTRYX, INC. (US) 2010-07-29 US disclosed
US-7718683-B2 Triazolyl phenyl benzenesulfonamides CHEMOCENTRYX, INC. (US) 2010-05-18 US disclosed
US-7718683-B2 Triazolyl phenyl benzenesulfonamides CHEMOCENTRYX, INC. (US) 2010-05-18 US disclosed
US-7718683-B2 Triazolyl phenyl benzenesulfonamides CHEMOCENTRYX, INC. (US) 2010-05-18 US disclosed
EP-2046762-A2 TRIAZOLYL PHENYL BENZENESULFONAMIDES ChemoCentryx Inc (US) 2009-04-15 EP disclosed
US-20080039465-A1 TRIAZOLYL PHENYL BENZENESULFONAMIDES CHEMOCENTRYX, INC. 2008-02-14 US disclosed
US-20080039465-A1 TRIAZOLYL PHENYL BENZENESULFONAMIDES CHEMOCENTRYX, INC. 2008-02-14 US disclosed
US-20080039465-A1 TRIAZOLYL PHENYL BENZENESULFONAMIDES CHEMOCENTRYX, INC. 2008-02-14 US disclosed
WO-2008010934-A2 TRIAZOLYL PHENYL BENZENESULFONAMIDES CHEMOCENTRYX, INC. (US) 2008-01-24 WO disclosed
WO-2008010934-A2 TRIAZOLYL PHENYL BENZENESULFONAMIDES CHEMOCENTRYX, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165303-A1 TRIAZOLYL PHENYL BENZENESULFONAMIDES CCR9, CCR2, CCR1 HSD17B2 3849/4885MEN1 4877/4885KMT2A 3579/4885
US-20100190762-A1 TRIAZOLYL PHENYL BENZENESULFONAMIDES CCR9, CCR2, CCR1 HSD17B2 3849/4885MEN1 4877/4885KMT2A 3579/4885
US-20080039465-A1 TRIAZOLYL PHENYL BENZENESULFONAMIDES CCR9, CCR2, CCR1 HSD17B2 3849/4885MEN1 4877/4885KMT2A 3579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.